Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
Studying Anti-neutrophil cytoplasmic antibody-associated vasculitis
Last synced from ClinicalTrials.gov
Key facts
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Principal Investigator
- Arielle Mendel, MD MScMcGill University
- Enrollment
- 201 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2025
Study locations (9)
- University of Calgary, Calgary, Alberta, Canada
- University of Alberta, Edmonton, Alberta, Canada
- University of British Columbia (Vancouver Coastal Health Authority), Vancouver, British Columbia, Canada
- St Joseph's Healthcare Hamilton (McMaster University), Hamilton, Ontario, Canada
- Lawson Research Institute (Western University), London, Ontario, Canada
- Ottawa Hospital Research Institute (Ottawa University), Ottawa, Ontario, Canada
- Sinai Health System (University of Toronto), Toronto, Ontario, Canada
- McGill University (Montreal General Hospital), Montreal, Quebec, Canada
- Centre Intégré Universitaire de Santé et de Services Sociaux du Nord-de-l'île-de-Montréal (CIUSSS NÎM) / Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada
Collaborators
Sinai Health System · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal · St. Joseph's Healthcare Hamilton · University of Calgary · University of British Columbia · University of Alberta · Ottawa Hospital Research Institute · CAnadian Network for Advanced Interdisciplinary Methods for comparative effectiveness research · Canadian Initiative for Outcomes in Rheumatology Care
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05716334 on ClinicalTrials.govOther trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07556484Pharmacokinetics Of Emulsified Avacopan Applied By NG TubeMayo Clinic
- RECRUITINGEARLY PHASE1NCT07507201Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune DiseaseThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNCT07258524PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated VasculitisUniversity of Edinburgh
- RECRUITINGPHASE1NCT07315087CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune DiseasesInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07160608Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE3NCT06983821Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)Ottawa Hospital Research Institute
- RECRUITINGPHASE3NCT07168161BDB-001 Phase III Trial in ANCA-Associated VasculitisStaidson (Beijing) Biopharmaceuticals Co., Ltd
- RECRUITINGNCT07151521(68)Ga-FAPI PET/CT in Patients With ANCA-associated VasculitisRuijin Hospital
See all trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis →